中播控股(00471.HK)取消授出1089.6萬份購股權
格隆匯 8 月 11日丨中播控股(00471.HK)公告,內容有關授出合共1089.6萬份購股權。
根據上市規則第17.05條,公司在得悉內幕消息後不得授出期權,直至有關消息公佈為止;尤其是不得在以下較早日期前一個月內授出期權:(1)董事會為通過發行人任何年度、半年度、季度及任何其他中期業績(不論是否《上市規則》所規定者)舉行的會議日期(即發行人根據《上市規則》最先通知交易所將舉行的董事會會議日期);及(2)發行人根據《上市規則》規定公佈年度或半年度業績的限期,或公佈季度或任何其他中期業績(不論是否《上市規則》所規定者)的限期。擬授出的新購股權未獲相關承授人接納而未被實現。
擬授出的購股權被公司因應取消。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.